ASH Annual Meeting and Exposition brings you the highlights from the American Society of Hematology Annual Meeting and Exposition. Refer back to this page often to read the latest news from ASH, see perspectives and interviews with leading researchers and clinicians, and review archives of past meetings.

Meeting News

Long-term ibrutinib appears effective in lymphoma subtype

February 23, 2018
ATLANTA — Long-term follow-up demonstrated that more than a quarter of patients with relapsed/refractory mantle cell lymphoma treated with…
Meeting News

Progression of disease may be effective endpoint for poor survival in lymphoma subtype

February 22, 2018
ATLANTA — Progression of disease within 24 months of diagnosis among patients treated with chemoimmunotherapy appears to be an effective early…
Meeting News

Gene mutations may improve prognosis models for certain patients with leukemia subtype

February 20, 2018
ATLANTA — Contrary to previous research, treatment with hypomethylating agents seem to only partially negate the poor prognosis of certain…
Meeting News

CAR T cells appear effective in leukemia subtype

February 20, 2018
ATLANTA — Chimeric antigen receptor T cells have been at the forefront of immunotherapy for the treatment of B-cell malignancies, according to…
Meeting NewsPerspective

Racial disparities persist in stem cell transplant for multiple myeloma

February 19, 2018
ATLANTA — More non-Hispanic whites underwent hematopoietic stem cell transplant for initial therapy for multiple myeloma compared with…
Meeting News

Addition of IDH inhibitors to standard chemotherapy improves outcomes in leukemia subtype

February 16, 2018
ATLANTA — Ivosidenib or enasidenib used in combination with standard induction therapy provided encouraging response rates and appeared well…
Meeting NewsVideo

BTK inhibitors provide ‘exciting time’ for the treatment of lymphoma subtype

February 10, 2018
ATLANTA — Three studies evaluating the use of different Bruton’s tyrosine kinase inhibitors presented at the ASH Annual Meeting and…
Meeting News

Study results may lead to ‘completely different way’ of treating lymphoma subtype

February 9, 2018
ATLANTA — The recent approvals of axicabtagene ciloleucel and tisagenlecleucel T-suspension highlight the efficacy of CAR T-cell therapies for
Meeting News

Brentuximab vedotin, ibrutinib combination appears effective for Hodgkin lymphoma

February 6, 2018
ATLANTA — A combination of brentuximab vedotin with ibrutinib appeared tolerable and safe among patients with relapsed or refractory Hodgkin…
Meeting News

Better targeted therapies likely coming for lymphoma subtype

February 5, 2018
ATLANTA — Advances in the treatment of mantle cell lymphoma comprised several studies presented at the ASH Annual Meeting and Exposition. …

Meeting Calendar

ASH Annual Meeting and Exposition

December 1, 2018 - December 4, 2018

  • Location: San Diego, Calif.
  • Website